ConductScience.org, home

Gene · 6755

SSTR5: somatostatin receptor 5

12 sourcesgene-search-2026-11-11-0.2.0

Download JSON
Cite this record

ConductScience Library. SSTR5: somatostatin receptor 5. Genes, record 6755. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/6755

On this page

Gene

Symbol
SSTR5
HGNC
Name
somatostatin receptor 5
HGNC
NCBI Gene ID
6755
NCBI Gene
HGNC ID
HGNC:11334
HGNC
Ensembl
ENSG00000162009
NCBI Gene
Aliases
SS-5-R, SST5
NCBI Gene
Type
protein-coding
NCBI Gene

Proteins1

Reviewed human proteins whose Swiss-Prot entry states the gene.

UniProt entryProteinLengthStructuresGene stated in
P35346Somatostatin receptor type 53647Ensembl, GeneID, HGNC

Source UniProt

Patents63

Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.

PublicationPublishedSEQ ID NOProteinSource
JP 2026004568 A2026-01-1464918P35346Espacenet
JP 2026004568 A2026-01-1464919P35346Espacenet
JP 2025529142 A2025-09-044458P35346Espacenet
US 12371689 B22025-07-294458P35346Espacenet
US 12121590 B22024-10-22123P35346Espacenet
US 11701430 B22023-07-18123P35346Espacenet
US 11541119 B22023-01-0320P35346Espacenet
US 11446398 B22022-09-2082337P35346Espacenet
US 11400116 B22022-08-02937P35346Espacenet
JP 2022524081 A2022-04-27185308P35346Espacenet

1 to 10 of 63

See all 63 patents

Drugs13

Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.

DrugChEMBL IDMechanismActionSource
LANREOTIDECHEMBL1201185Somatostatin receptor 5 agonistAGONISTChEMBL
LANREOTIDE ACETATECHEMBL1201184Somatostatin receptor 5 agonistAGONISTChEMBL
LUTETIUM OXODOTREOTIDECHEMBL4302409Somatostatin receptor binding agentBINDING AGENTChEMBL
LUTETIUM OXODOTREOTIDE LU-177CHEMBL4297545Somatostatin receptor binding agentBINDING AGENTChEMBL
OCTREOTIDECHEMBL1680Somatostatin receptor agonistAGONISTChEMBL
OCTREOTIDE ACETATECHEMBL1200480Somatostatin receptor agonistAGONISTChEMBL
ONZIGOLIDECHEMBL4650342Somatostatin receptor 5 agonistAGONISTChEMBL
PASIREOTIDECHEMBL3349607Somatostatin receptor 5 agonistAGONISTChEMBL
PASIREOTIDE DIASPARTATECHEMBL5314380Somatostatin receptor 5 agonistAGONISTChEMBL
PASIREOTIDE PAMOATECHEMBL5314382Somatostatin receptor 5 agonistAGONISTChEMBL

1 to 10 of 13

See all 13 drugs

Trials390

Trials of those drugs. A trial joins the gene only through a drug that acts on it.

TrialDrugPhaseResults first postedSource
NCT07595237LUTETIUM OXODOTREOTIDE LU-177EARLY_PHASE1ClinicalTrials.gov
NCT07583563OCTREOTIDEClinicalTrials.gov
NCT07537010LUTETIUM OXODOTREOTIDE LU-177PHASE1ClinicalTrials.gov
NCT07534371SOMATOSTATINClinicalTrials.gov
NCT07460908OCTREOTIDEClinicalTrials.gov
NCT07316686LUTETIUM OXODOTREOTIDE LU-177PHASE1ClinicalTrials.gov
NCT07304466SOMATOSTATINClinicalTrials.gov
NCT07252401SOMATOSTATINClinicalTrials.gov
NCT07229768LUTETIUM OXODOTREOTIDE LU-177EARLY_PHASE1ClinicalTrials.gov
NCT07189871LUTETIUM OXODOTREOTIDE LU-177PHASE1/PHASE2ClinicalTrials.gov

1 to 10 of 390

See all 390 trials

NIH grants448

NIH grants whose papers are about the gene, through NIH's grant-paper links.

GrantTitleSSTR5 papersNewest fiscal year
P30CA008748Cancer Center Support Grant72025
P30CA086862Cancer Center Support Grant52025
P30DK084567Mayo Center for Cell Signaling in Gastroenterology42025
P30CA016672Cancer Center Support Grant32025
R01DA008863Regulation Of Opioid Receptor Signaling by Endogenous Peptides32025
K12CA086913Paul Calabresi Award in Clinical Oncology Research22025
P30CA013148Comprehensive Cancer Center Support Grant22025
P30CA023074University of Arizona Cancer Center - Cancer Center Support Grant22025
R01CA134675Enhanced imaging and treatment of aggressive subtypes of prostate cancer22025
ZIADK053200Diagnosis, Natural History, Management, tumor biology of Gastrinomas/PETs/Neuroendocrine tumors22025

1 to 10 of 448Source NIH's project files

See all 448 nih grants

Papers1,882

Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.

TitleJournalYearPMIDFound bySource
Predictors of in vitro response to somatostatin and dopamine receptor-targeted treatments are lacking in clinically non-functioning pituitary tumors.J Neuroendocrinol202642785810PubTator, text miningPubMed
Tirzepatide for pasireotide-induced hyperglycemia in a GH/TSH-producing pituitary adenoma/PitNET: a case report and literature review.Endocr J202642732962PubTator, text miningPubMed
Case Report: Pasireotide treatment in neonatal congenital hyperinsulinism due to a homozygous ABCC8 mutation.Front Endocrinol (Lausanne)202642723843PubTator, text miningPubMed
Microbiota contributes to regulates the external genitalia development through gut-testis axis in male geese.Poult Sci202642617270PubTator, text miningPubMed
Multi-omics integration unravels four molecular subgroups of corticotroph pituitary neuroendocrine tumours with distinct clinicopathological features.Nat Commun202642552318PubTator, text miningPubMed
Epigenetic Dysregulation of Somatostatin Receptors (SSTR) 1-5 and Therapeutic Implications in Neuroendocrine and Non-Neuroendocrine Malignancies.Int J Cancer202642400125PubTator, text miningPubMed
Expression of ATRX, DAXX, PDX1, ARX, and somatostatin receptors in pancreatic neuroendocrine tumors: a clinicopathological study.Front Endocrinol (Lausanne)202642199802PubTator, text miningPubMed
Structural and Functional Basis of SSTR5 Homodimerization in Controlling Receptor Signaling and Pasireotide Response in Corticotroph Adenomas.FASEB J202642141916PubTator, text miningPubMed
Somatostatin and Its Analogues as Second-Line Treatments in Non-Neoplastic Conditions.Int J Mol Sci202642123401PubTator, text miningPubMed
Impact of Neuroendocrine Neoplasm-Specific Systemic Treatments on Somatostatin Receptors Expression and Function in Neuroendocrine Tumor Cells.Cancers (Basel)202642122164PubTator, text miningPubMed

1 to 10 of 1,882

See all 1,882 papers

Sources 12

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
  • GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
  • HGNCCC0
  • NCBI GenePublic domain (US government)
  • NIH's project files and grant-paper linksPublic domain
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
  • GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
  • HGNCCC0: https://www.genenames.org/about/license/
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this gene from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/genes/v1/6755

GET https://conductscience.org/api/genes/v1/6755/patents?page=2